Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQRFJWek5pTm92Nm0xVUNQWWlNRDZZaVktb1JBOHhCSlEzOEJoUXZBakRwSF9TeXpualljSVR6RThqeEFOQ29yYzZ5NTYwQmdSQlVYSTFOdWNfZm1yT1VGMldWR0xzaDVsQzVGS3YxZjBUVFQyMEt1aDJlQ000WG1rZGVJTmpaNnRocmh5RFBvYjI1ek5XRkNxczM2WjZGckVTQ01henNGdWJSVHhZTGxIcXJsa0k4bGZ0UWtNbVdNRlhMQlliQ0dRWE9qU1VURWwxTlhfaFdR?oc=5" target="_blank">Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
US FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 25, 2026 at 10:57 PMUS FDA extends review of Novo Nordisk's hemophilia drug over facility issues - Reuters
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues Reuters
October 2, 2026 at 09:52 PMRegeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial - reuters.com
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial reuters.com
September 30, 2026 at 10:30 PMLilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com
Lilly's experimental drug cuts weight by 21% in diabetes trial reuters.com
September 29, 2026 at 10:15 PMExperimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
September 30, 2026 at 05:34 PMNovo Nordisk to license experimental GLP-1 pill from China's Hengrui - Reuters
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui Reuters
September 29, 2026 at 04:47 AM